- Adicet Bio Inc (NASDAQ:ACET) announced safety and efficacy data from its Phase 1 study of ADI-001 for relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL).
- ADI-001 demonstrated a 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL.
- In five LBCL patients that previously relapsed after prior autologous anti-CD19 CAR T therapy, treatment with ADI-001 demonstrated 100% ORR and CR rate (5/5).
- ADI-001 resulted in CR in patients who previously showed a partial response (PR) to autologous CAR T (2/2).
- An 86% CR rate (6/7) was observed in large B-cell lymphoma (LBCL) patients across dose level three (DL3) and above. 75% CR rate (9/12) in LBCL across all dose levels.
- DL2 and DL3 demonstrated a six-month CR rate of 33%; Patient follow-up continues in DL4 to assess six-month durability.
- Adicet plans to initiate a potentially pivotal study in post-CAR T LBCL patients in the second quarter of 2023.
- Price Action: ACET shares are down 36.90% at $10.30 on the last check Monday.
AstraZeneca Announced Danicopan As Add-on To Ultomiris Or Soliris Improved Haemoglobin Levels And Maintained Disease Control In Patients With PNH Experiencing Signs Of Clinically Significant Extravascular Haemolysis
Results from ALPHA Phase III trial demonstrated statistically significant increase compared to placebo in mean haemoglobin from baseline to week 12. All key secondary endpoints met statistical superiority, showing
